What Is Thalassaemia and How Is It Diagnosed Through HPLC Testing?
A Condition That Affects Millions of Pakistanis — Yet Remains Widely Misunderstood
Thalassaemia is one of the most common inherited blood disorders in Pakistan. It affects hundreds of thousands of families across the country, and Pakistan has one of the highest carrier rates of beta-thalassaemia in the world — estimates suggest that approximately five to eight percent of the Pakistani population carries the thalassaemia trait without knowing it. In Lahore alone, new cases of thalassaemia major are diagnosed every week in children whose parents had no idea they were both carriers before their child was born.
Despite its prevalence, thalassaemia remains poorly understood by the general public. Many patients and families receive a diagnosis without a clear explanation of what the condition actually involves, why it causes the problems it does, or what the difference is between being a carrier and having the disease. This guide provides that explanation — and explains why HPLC testing at Alnoor Diagnostic Centre in Shadman, Lahore is the most accurate and reliable method of diagnosis currently available.
What Is Thalassaemia — The Biology in Plain Language
Thalassaemia is an inherited disorder of haemoglobin — the protein inside red blood cells that carries oxygen. Normal adult haemoglobin is composed of two alpha-globin chains and two beta-globin chains bound together around an iron-containing haem group. This structure is precisely engineered to bind oxygen efficiently in the lungs and release it in the tissues.
Thalassaemia results from genetic mutations that reduce or eliminate the production of one of these globin chain types. When insufficient globin chains are produced, haemoglobin assembly is disrupted. The unpaired excess chains are unstable — they precipitate within developing red blood cells, damaging them and causing their premature destruction. The result is a chronic haemolytic anaemia whose severity depends entirely on how many of the relevant genes are affected.
Beta-thalassaemia involves mutations affecting the beta-globin genes on chromosome 11. Alpha-thalassaemia involves deletions or mutations affecting the alpha-globin genes on chromosome 16. Beta-thalassaemia is by far the more clinically significant form in Pakistan and is the primary focus of thalassaemia diagnosis and prevention programmes across the country.
The Spectrum of Beta-Thalassaemia — Trait, Intermedia, and Major
Understanding that beta-thalassaemia is not a single condition but a spectrum of severity ranging from a clinically silent carrier state to a life-threatening transfusion-dependent disease is essential for patients and families to grasp.
Beta-thalassaemia trait — also called beta-thalassaemia minor — occurs when one of the two beta-globin genes carries a thalassaemia mutation while the other remains normal. Carriers produce sufficient haemoglobin for normal or near-normal red cell function. They typically have mild anaemia with a characteristically low MCV and low MCH — small, pale red cells — that is frequently mistaken for iron deficiency anaemia and treated with iron supplements that have no benefit. Carriers are healthy individuals who may be unaware of their carrier status throughout their lives unless specifically tested.
The critical clinical importance of carrier status is reproductive. When two carriers of beta-thalassaemia trait have children, each pregnancy carries a one in four chance of producing a child with beta-thalassaemia major — and a one in two chance of producing another carrier. Every couple where both partners are carriers faces this statistical reality with every pregnancy.
Beta-thalassaemia major — also called Cooley’s anaemia — occurs when both beta-globin genes carry thalassaemia mutations, completely or severely impairing beta-chain production. Affected children are born appearing normal but develop severe, life-threatening anaemia in the first months of life as foetal haemoglobin — which uses gamma chains rather than beta chains — is replaced by adult haemoglobin whose beta chains cannot be produced. Without treatment, children with thalassaemia major would not survive. With treatment — regular blood transfusions every three to four weeks and iron chelation therapy to manage the iron overload that accumulates from repeated transfusions — they can live into adulthood, though the treatment burden is enormous and lifelong.
Beta-thalassaemia intermedia falls between these two extremes — patients have significant anaemia and symptoms but can survive without regular transfusions, at least in the early years of the disease.
The Scale of the Problem in Pakistan
Pakistan has the second highest number of thalassaemia major children in the world. Approximately five thousand new thalassaemia major babies are born in Pakistan every year. The primary reason for this burden is the marriage of two carriers — often within extended family networks where the same thalassaemia mutations run through both sides of the family — without pre-marital or pre-pregnancy carrier screening.
The tragedy of each new thalassaemia major birth is that it is preventable. Identifying both parents as carriers before or early in pregnancy allows informed decision-making and, where appropriate, prenatal diagnosis. But identification requires accurate carrier testing — and this is where HPLC plays its essential role.
Why the Standard CBC Misses Thalassaemia Trait
The classic CBC finding in beta-thalassaemia trait is a microcytic, hypochromic anaemia with a low MCV, low MCH, and normal or elevated red cell count. This pattern is clinically indistinguishable from iron deficiency anaemia on the CBC alone — and iron deficiency is so prevalent in Pakistan that the thalassaemia carrier is almost invariably assumed to be iron deficient and prescribed iron supplements.
The fundamental difference is this — iron deficiency anaemia responds to iron supplementation and thalassaemia trait does not. A patient who has been given iron for months without improvement of their anaemia deserves thalassaemia testing. But waiting for treatment failure before testing means months of unnecessary medication and delayed diagnosis.
HPLC directly identifies the abnormal haemoglobin variants and quantifies haemoglobin fractions that distinguish thalassaemia from iron deficiency without ambiguity — making the diagnosis definitively at the time of testing rather than retrospectively after failed treatment.
What Is HPLC and How Does It Work?
HPLC stands for High Performance Liquid Chromatography. It is a laboratory analytical technique that separates and quantifies the different haemoglobin fractions present in a blood sample based on their individual physical and chemical properties.
In the HPLC analyser, a small sample of blood is injected into a column containing a specialised material through which a liquid solvent flows under high pressure. Different haemoglobin variants — HbA, HbA2, HbF, HbS, HbC, HbE, and others — have slightly different molecular charges and interact differently with the column material, causing them to travel through the column at different speeds. As each fraction elutes — exits the column — it passes through a detector that measures its concentration. The result is a chromatogram — a graph showing peaks corresponding to each haemoglobin fraction — with precise quantification of the percentage of each type present.
The entire analysis takes approximately six minutes per sample. The output is highly reproducible, operator-independent, and provides a permanent digital record of the chromatographic pattern.
What HPLC Reveals in Thalassaemia Diagnosis
Beta-thalassaemia trait — The hallmark of beta-thalassaemia minor on HPLC is an elevated HbA2 fraction — typically between 3.5 and 7.0 percent, compared to the normal range of 2.0 to 3.3 percent. This elevation occurs because when beta-chain production is reduced, the body compensates by producing relatively more delta chains — which combine with alpha chains to form HbA2. This characteristic and reliable elevation of HbA2 is the definitive diagnostic finding for beta-thalassaemia trait and is clearly and accurately quantified by HPLC.
Beta-thalassaemia major and intermedia — In more severe forms, HbA is severely reduced or absent, HbF — foetal haemoglobin — is markedly elevated as the body desperately maintains whatever haemoglobin production it can using gamma chains, and the overall haemoglobin profile is profoundly abnormal. The HPLC pattern in thalassaemia major is unmistakable.
Delta-beta thalassaemia — This variant produces a characteristic pattern with absent or reduced HbA2 alongside markedly elevated HbF, distinguishable from simple beta-thalassaemia trait on the HPLC chromatogram.
Haemoglobin E — HbE is the most common structural haemoglobin variant in South and Southeast Asia. When inherited together with a beta-thalassaemia mutation — a condition called HbE-beta thalassaemia — it produces significant disease. HPLC identifies and quantifies HbE precisely, which is critical because HbE-beta thalassaemia is clinically important in Pakistan’s population and was previously difficult to diagnose reliably.
Sickle cell disease and sickle cell trait — HbS — the abnormal haemoglobin of sickle cell disease — is detected and quantified by HPLC with high accuracy. While sickle cell disease is less prevalent than thalassaemia in Pakistan, it occurs and requires accurate identification for clinical management and genetic counselling.
Haemoglobin variants in general — HPLC detects and characterises a wide range of structural haemoglobin variants beyond those listed above, providing a comprehensive haemoglobinopathy screen from a single test.
When Should HPLC Testing Be Done?
Every individual with unexplained microcytic hypochromic anaemia that has not responded to iron supplementation should have HPLC testing. Every person with a family history of thalassaemia should be tested regardless of whether their CBC appears abnormal. Premarital and pre-pregnancy HPLC screening of both partners is the most important application of the test from a public health perspective — identifying carrier couples before pregnancy allows informed reproductive decision-making and is the foundation of thalassaemia prevention.
Pregnant women with microcytic anaemia should have HPLC performed urgently — if thalassaemia trait is confirmed, the partner must be tested immediately, and if both are carriers, prenatal diagnosis options must be discussed without delay. Children with severe unexplained anaemia in the first year of life require HPLC as part of the urgent diagnostic workup.
HPLC Testing at Alnoor Diagnostic Centre, Lahore
At Alnoor Diagnostic Centre in Shadman, Lahore, we provide HPLC haemoglobinopathy testing using modern automated analysers operated by experienced laboratory scientists. Our results are precise, reproducible, and reported with the clinical detail that haematologists, paediatricians, obstetricians, and genetic counsellors across the city depend on for accurate diagnosis and counselling.
Whether you are seeking testing for yourself, for premarital screening, during pregnancy, or for a child with unexplained anaemia, our team is here to provide the most accurate diagnosis available — promptly and professionally.